Kathryn Hassell
Concepts (536)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 49 | 2026 | 318 | 6.900 |
Why?
| | Water Pollutants, Chemical | 13 | 2022 | 227 | 2.100 |
Why?
| | Antiphospholipid Syndrome | 5 | 2023 | 37 | 1.690 |
Why?
| | Migraine Disorders | 2 | 2023 | 114 | 1.240 |
Why?
| | Perciformes | 5 | 2018 | 20 | 1.100 |
Why?
| | Anticoagulants | 8 | 2021 | 748 | 1.090 |
Why?
| | Heparin | 5 | 2011 | 247 | 1.060 |
Why?
| | Thrombocytopenia | 5 | 2014 | 204 | 1.050 |
Why?
| | Hypertension, Pulmonary | 14 | 2026 | 1957 | 1.040 |
Why?
| | Antibodies, Antiphospholipid | 4 | 2023 | 29 | 0.990 |
Why?
| | Fishes | 4 | 2021 | 110 | 0.990 |
Why?
| | Hemoglobins | 9 | 2026 | 386 | 0.820 |
Why?
| | Estrogens | 3 | 2016 | 367 | 0.770 |
Why?
| | Hydroxyurea | 5 | 2016 | 34 | 0.750 |
Why?
| | Hemopexin | 4 | 2025 | 38 | 0.730 |
Why?
| | Pyridones | 2 | 2021 | 209 | 0.680 |
Why?
| | Disorders of Sex Development | 2 | 2018 | 40 | 0.660 |
Why?
| | Blood Transfusion | 7 | 2015 | 409 | 0.650 |
Why?
| | Hirudins | 4 | 2011 | 53 | 0.650 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 238 | 0.630 |
Why?
| | Testis | 2 | 2018 | 162 | 0.620 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 297 | 0.620 |
Why?
| | Caprylates | 1 | 2020 | 19 | 0.620 |
Why?
| | Alkanesulfonic Acids | 1 | 2020 | 35 | 0.610 |
Why?
| | Environmental Monitoring | 8 | 2025 | 347 | 0.590 |
Why?
| | Pyrazoles | 2 | 2021 | 517 | 0.590 |
Why?
| | Oocytes | 2 | 2021 | 185 | 0.550 |
Why?
| | Fluorocarbons | 1 | 2020 | 120 | 0.550 |
Why?
| | Quality of Life | 6 | 2017 | 3211 | 0.530 |
Why?
| | Neonatal Screening | 3 | 2020 | 179 | 0.520 |
Why?
| | Haptoglobins | 4 | 2026 | 71 | 0.520 |
Why?
| | Cyprinidae | 1 | 2016 | 22 | 0.480 |
Why?
| | Australia | 10 | 2022 | 291 | 0.470 |
Why?
| | Pain | 5 | 2023 | 791 | 0.470 |
Why?
| | beta-Thalassemia | 2 | 2025 | 40 | 0.400 |
Why?
| | Pain Measurement | 3 | 2017 | 562 | 0.400 |
Why?
| | Embryo, Nonmammalian | 2 | 2019 | 171 | 0.400 |
Why?
| | Hypoxia | 5 | 2026 | 1199 | 0.400 |
Why?
| | Health Status Indicators | 1 | 2014 | 167 | 0.400 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 6085 | 0.390 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 130 | 0.390 |
Why?
| | Humans | 79 | 2026 | 145783 | 0.370 |
Why?
| | Tricuspid Valve Insufficiency | 3 | 2011 | 24 | 0.370 |
Why?
| | Vascular Remodeling | 3 | 2026 | 209 | 0.360 |
Why?
| | Adult | 41 | 2025 | 40881 | 0.360 |
Why?
| | Peptide Fragments | 4 | 2014 | 697 | 0.350 |
Why?
| | Sewage | 2 | 2025 | 30 | 0.340 |
Why?
| | Antithrombins | 2 | 2011 | 71 | 0.340 |
Why?
| | Animals | 31 | 2026 | 38101 | 0.340 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.330 |
Why?
| | Thrombosis | 4 | 2021 | 400 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 740 | 0.320 |
Why?
| | Nomograms | 1 | 2011 | 59 | 0.320 |
Why?
| | Male | 48 | 2025 | 73010 | 0.320 |
Why?
| | Censuses | 1 | 2010 | 33 | 0.310 |
Why?
| | Endocrine Disruptors | 3 | 2016 | 41 | 0.300 |
Why?
| | Rivaroxaban | 2 | 2025 | 271 | 0.290 |
Why?
| | Vitellogenins | 3 | 2016 | 11 | 0.290 |
Why?
| | Female | 43 | 2025 | 79045 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2025 | 328 | 0.280 |
Why?
| | Heme | 3 | 2025 | 90 | 0.280 |
Why?
| | Health Priorities | 1 | 2009 | 41 | 0.280 |
Why?
| | Thrombophilia | 3 | 2007 | 89 | 0.280 |
Why?
| | Anemia, Hemolytic | 2 | 2026 | 21 | 0.280 |
Why?
| | Young Adult | 18 | 2025 | 14254 | 0.270 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2008 | 13 | 0.270 |
Why?
| | Estuaries | 2 | 2021 | 2 | 0.260 |
Why?
| | Iron | 4 | 2025 | 359 | 0.260 |
Why?
| | Gonads | 2 | 2018 | 22 | 0.260 |
Why?
| | Self Care | 1 | 2010 | 392 | 0.260 |
Why?
| | Biodiversity | 2 | 2021 | 311 | 0.260 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2005 | 58 | 0.260 |
Why?
| | Nitric Oxide | 2 | 2018 | 892 | 0.260 |
Why?
| | Population Surveillance | 2 | 2010 | 484 | 0.260 |
Why?
| | Stroke | 3 | 2021 | 1271 | 0.250 |
Why?
| | Macrophages | 3 | 2026 | 1507 | 0.250 |
Why?
| | Sickle Cell Trait | 2 | 2018 | 15 | 0.250 |
Why?
| | Fresh Water | 3 | 2020 | 53 | 0.250 |
Why?
| | Hospitalists | 1 | 2011 | 267 | 0.250 |
Why?
| | Kinetics | 2 | 2020 | 1568 | 0.240 |
Why?
| | Middle Aged | 25 | 2025 | 36309 | 0.240 |
Why?
| | Environmental Pollutants | 2 | 2019 | 139 | 0.240 |
Why?
| | Phospholipids | 1 | 2008 | 214 | 0.240 |
Why?
| | Insecta | 1 | 2006 | 71 | 0.240 |
Why?
| | Estradiol | 4 | 2016 | 515 | 0.230 |
Why?
| | Acoustics | 1 | 2026 | 48 | 0.230 |
Why?
| | Lung | 5 | 2026 | 4116 | 0.230 |
Why?
| | Fats | 1 | 2025 | 13 | 0.230 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.230 |
Why?
| | Patient Education as Topic | 1 | 2010 | 777 | 0.220 |
Why?
| | Cation Transport Proteins | 1 | 2026 | 118 | 0.220 |
Why?
| | Adolescent | 20 | 2025 | 22577 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 699 | 0.220 |
Why?
| | Estrone | 2 | 2016 | 41 | 0.210 |
Why?
| | Health Services Accessibility | 3 | 2016 | 1101 | 0.210 |
Why?
| | Spleen | 2 | 2025 | 508 | 0.210 |
Why?
| | Hospitalization | 4 | 2025 | 2461 | 0.210 |
Why?
| | Cadmium | 2 | 2021 | 68 | 0.190 |
Why?
| | Hypertrichosis | 1 | 2023 | 9 | 0.190 |
Why?
| | Hemoglobinopathies | 1 | 2023 | 6 | 0.190 |
Why?
| | Acromegaly | 1 | 2023 | 17 | 0.190 |
Why?
| | Antisickling Agents | 2 | 2016 | 7 | 0.190 |
Why?
| | Headache | 2 | 2023 | 151 | 0.190 |
Why?
| | Limb Deformities, Congenital | 1 | 2023 | 22 | 0.190 |
Why?
| | Factor Xa Inhibitors | 1 | 2025 | 194 | 0.190 |
Why?
| | Hemostasis | 2 | 2007 | 98 | 0.190 |
Why?
| | Wetlands | 2 | 2022 | 33 | 0.190 |
Why?
| | Bays | 3 | 2017 | 7 | 0.180 |
Why?
| | Volatile Organic Compounds | 1 | 2023 | 48 | 0.180 |
Why?
| | Child | 20 | 2024 | 22740 | 0.180 |
Why?
| | Pesticides | 1 | 2022 | 59 | 0.180 |
Why?
| | Psychometrics | 3 | 2016 | 732 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2933 | 0.180 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1368 | 0.180 |
Why?
| | Mass Screening | 1 | 2011 | 1361 | 0.180 |
Why?
| | Arginine | 2 | 2015 | 264 | 0.170 |
Why?
| | Hemolysis | 4 | 2021 | 242 | 0.170 |
Why?
| | Metallothionein | 1 | 2021 | 25 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 90 | 0.160 |
Why?
| | alpha-Thalassemia | 1 | 2020 | 5 | 0.160 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2021 | 82 | 0.160 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.160 |
Why?
| | Acute Pain | 1 | 2021 | 58 | 0.160 |
Why?
| | Fertility Preservation | 1 | 2021 | 55 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2021 | 71 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 171 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 513 | 0.150 |
Why?
| | Ecotoxicology | 1 | 2019 | 3 | 0.150 |
Why?
| | Partial Thromboplastin Time | 2 | 2011 | 53 | 0.150 |
Why?
| | Infertility, Female | 1 | 2021 | 122 | 0.150 |
Why?
| | Disease Models, Animal | 7 | 2026 | 4568 | 0.150 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 29 | 0.150 |
Why?
| | Clove Oil | 1 | 2019 | 1 | 0.150 |
Why?
| | Eugenol | 1 | 2019 | 4 | 0.150 |
Why?
| | Iron Chelating Agents | 2 | 2011 | 17 | 0.150 |
Why?
| | Cyprinodontiformes | 1 | 2019 | 5 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2005 | 120 | 0.150 |
Why?
| | Aged | 11 | 2025 | 26217 | 0.150 |
Why?
| | Iron Overload | 2 | 2011 | 19 | 0.150 |
Why?
| | Benzoates | 2 | 2011 | 51 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2011 | 283 | 0.140 |
Why?
| | Unrelated Donors | 1 | 2019 | 39 | 0.140 |
Why?
| | Prospective Studies | 9 | 2025 | 8078 | 0.140 |
Why?
| | Plastics | 1 | 2019 | 50 | 0.140 |
Why?
| | Liver | 3 | 2025 | 1899 | 0.140 |
Why?
| | Altitude | 3 | 2018 | 463 | 0.140 |
Why?
| | Hemorrhage | 2 | 2021 | 822 | 0.140 |
Why?
| | Signal Transduction | 2 | 2013 | 5224 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3418 | 0.140 |
Why?
| | Anesthetics | 1 | 2019 | 100 | 0.130 |
Why?
| | Europe | 2 | 2016 | 421 | 0.130 |
Why?
| | Triazoles | 2 | 2011 | 191 | 0.130 |
Why?
| | Practice Guidelines as Topic | 3 | 2015 | 1582 | 0.130 |
Why?
| | Bone Marrow Transplantation | 1 | 2019 | 298 | 0.130 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 271 | 0.130 |
Why?
| | Lipids | 2 | 2023 | 707 | 0.130 |
Why?
| | Aspirin | 1 | 2021 | 406 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 205 | 0.130 |
Why?
| | Lipoproteins | 1 | 2018 | 166 | 0.130 |
Why?
| | Factor Analysis, Statistical | 2 | 2016 | 292 | 0.130 |
Why?
| | Climate Change | 1 | 2019 | 177 | 0.130 |
Why?
| | Pulmonary Artery | 4 | 2019 | 1129 | 0.120 |
Why?
| | Platelet Factor 4 | 2 | 2008 | 36 | 0.120 |
Why?
| | Cohort Studies | 7 | 2018 | 6033 | 0.120 |
Why?
| | Prevalence | 4 | 2024 | 2875 | 0.120 |
Why?
| | Biomarkers | 6 | 2026 | 4302 | 0.120 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.120 |
Why?
| | Zinc | 1 | 2020 | 307 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2025 | 11794 | 0.120 |
Why?
| | Osmeriformes | 1 | 2016 | 1 | 0.120 |
Why?
| | Carps | 1 | 2016 | 4 | 0.120 |
Why?
| | Phenylketonurias | 1 | 2016 | 15 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 341 | 0.120 |
Why?
| | Asia | 1 | 2016 | 70 | 0.120 |
Why?
| | United States | 11 | 2023 | 16126 | 0.120 |
Why?
| | Principal Component Analysis | 2 | 2016 | 194 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 279 | 0.120 |
Why?
| | Olfactory Perception | 1 | 2016 | 18 | 0.120 |
Why?
| | Metals, Heavy | 1 | 2016 | 31 | 0.120 |
Why?
| | Rivers | 1 | 2016 | 62 | 0.120 |
Why?
| | Employment | 2 | 2014 | 184 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2019 | 668 | 0.120 |
Why?
| | Trace Elements | 1 | 2016 | 52 | 0.110 |
Why?
| | Erythrocyte Transfusion | 2 | 2015 | 225 | 0.110 |
Why?
| | Mice | 8 | 2026 | 18355 | 0.110 |
Why?
| | Anesthesia | 1 | 2019 | 257 | 0.110 |
Why?
| | Thalassemia | 1 | 2015 | 6 | 0.110 |
Why?
| | Infant, Newborn | 5 | 2024 | 6465 | 0.110 |
Why?
| | Copper | 1 | 2016 | 120 | 0.110 |
Why?
| | Lung Diseases | 2 | 2019 | 782 | 0.110 |
Why?
| | North America | 1 | 2016 | 304 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 992 | 0.110 |
Why?
| | Splenic Infarction | 1 | 2014 | 1 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 17330 | 0.110 |
Why?
| | Fatigue | 1 | 2017 | 366 | 0.110 |
Why?
| | Protein S Deficiency | 1 | 1994 | 8 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Zebrafish | 1 | 2019 | 532 | 0.110 |
Why?
| | Blood Component Removal | 1 | 2014 | 26 | 0.110 |
Why?
| | Complement Inactivator Proteins | 1 | 1994 | 39 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 191 | 0.100 |
Why?
| | Quality of Health Care | 2 | 2016 | 693 | 0.100 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 114 | 0.100 |
Why?
| | Leg Ulcer | 1 | 2013 | 4 | 0.100 |
Why?
| | Thromboembolism | 1 | 2014 | 129 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 105 | 0.100 |
Why?
| | Larva | 2 | 2019 | 240 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2014 | 421 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5992 | 0.100 |
Why?
| | Ethinyl Estradiol | 1 | 2012 | 16 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 849 | 0.090 |
Why?
| | Thrombin | 2 | 2023 | 172 | 0.090 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 119 | 0.090 |
Why?
| | Venous Thrombosis | 2 | 2005 | 196 | 0.090 |
Why?
| | Sex Factors | 3 | 2019 | 2110 | 0.090 |
Why?
| | Racism | 1 | 2014 | 147 | 0.090 |
Why?
| | Societies, Medical | 1 | 2017 | 900 | 0.090 |
Why?
| | Neoplasms | 2 | 2021 | 2913 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 416 | 0.090 |
Why?
| | Preoperative Care | 2 | 2005 | 380 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 292 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 498 | 0.090 |
Why?
| | Prostheses and Implants | 2 | 2021 | 137 | 0.090 |
Why?
| | Hemoglobin SC Disease | 3 | 1998 | 14 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 956 | 0.090 |
Why?
| | Pharmacists | 1 | 2014 | 258 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2016 | 610 | 0.080 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1154 | 0.080 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 532 | 0.080 |
Why?
| | Child, Preschool | 10 | 2024 | 11868 | 0.080 |
Why?
| | Mortality | 2 | 2012 | 381 | 0.080 |
Why?
| | Pipecolic Acids | 1 | 2011 | 26 | 0.080 |
Why?
| | Creatinine | 2 | 2014 | 515 | 0.080 |
Why?
| | Transfusion Reaction | 1 | 2011 | 61 | 0.080 |
Why?
| | Hemofiltration | 1 | 2010 | 24 | 0.080 |
Why?
| | Sulfones | 1 | 2011 | 127 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 627 | 0.080 |
Why?
| | Disease Progression | 4 | 2023 | 2865 | 0.080 |
Why?
| | Awareness | 1 | 2010 | 110 | 0.080 |
Why?
| | Disease Management | 2 | 2011 | 653 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2028 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2011 | 330 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2026 | 1360 | 0.070 |
Why?
| | Piperazines | 1 | 2011 | 375 | 0.070 |
Why?
| | Career Choice | 1 | 2010 | 235 | 0.070 |
Why?
| | United Kingdom | 3 | 2014 | 358 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 648 | 0.070 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 85 | 0.070 |
Why?
| | Drug Utilization Review | 1 | 2008 | 61 | 0.070 |
Why?
| | Anaerobiosis | 1 | 2008 | 65 | 0.070 |
Why?
| | Seawater | 1 | 2008 | 33 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 156 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 394 | 0.070 |
Why?
| | Pregnancy | 3 | 2005 | 7216 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1069 | 0.070 |
Why?
| | Software | 1 | 2013 | 680 | 0.070 |
Why?
| | Body Size | 1 | 2008 | 88 | 0.070 |
Why?
| | Community Participation | 1 | 2009 | 123 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8347 | 0.060 |
Why?
| | Cost of Illness | 1 | 2010 | 324 | 0.060 |
Why?
| | Depression | 1 | 2017 | 1559 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 123 | 0.060 |
Why?
| | Metabolomics | 1 | 2013 | 733 | 0.060 |
Why?
| | Lipid Peroxidation | 2 | 2018 | 168 | 0.060 |
Why?
| | Endothelial Cells | 1 | 2013 | 878 | 0.060 |
Why?
| | Proteomics | 2 | 2025 | 1188 | 0.060 |
Why?
| | Deferoxamine | 1 | 2007 | 27 | 0.060 |
Why?
| | Chironomidae | 1 | 2006 | 1 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2023 | 2064 | 0.060 |
Why?
| | Sulfonamides | 1 | 2011 | 583 | 0.060 |
Why?
| | Age Factors | 2 | 2014 | 3346 | 0.060 |
Why?
| | Environmental Exposure | 3 | 2019 | 578 | 0.060 |
Why?
| | Rhabdomyolysis | 2 | 2018 | 24 | 0.060 |
Why?
| | Acute Kidney Injury | 2 | 2010 | 874 | 0.060 |
Why?
| | Urbanization | 2 | 2016 | 28 | 0.060 |
Why?
| | Algorithms | 1 | 2014 | 1851 | 0.060 |
Why?
| | Social Support | 1 | 2010 | 651 | 0.060 |
Why?
| | Registries | 2 | 2023 | 2410 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| | Body Weight | 2 | 2021 | 972 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2008 | 328 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7134 | 0.060 |
Why?
| | Ecosystem | 2 | 2021 | 478 | 0.060 |
Why?
| | Fibrinolysis | 2 | 1998 | 164 | 0.060 |
Why?
| | Oils | 1 | 2025 | 22 | 0.060 |
Why?
| | Erythrocytes | 2 | 2026 | 749 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 536 | 0.060 |
Why?
| | Species Specificity | 1 | 2006 | 546 | 0.060 |
Why?
| | Dermatan Sulfate | 1 | 2005 | 4 | 0.060 |
Why?
| | Captopril | 1 | 2005 | 11 | 0.050 |
Why?
| | Factor V | 1 | 2005 | 26 | 0.050 |
Why?
| | Waste Disposal, Fluid | 1 | 2025 | 52 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 35 | 0.050 |
Why?
| | Survival Analysis | 1 | 2008 | 1378 | 0.050 |
Why?
| | Angina, Unstable | 1 | 2005 | 83 | 0.050 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 76 | 0.050 |
Why?
| | Risk | 2 | 2005 | 923 | 0.050 |
Why?
| | Polysaccharides | 1 | 2005 | 86 | 0.050 |
Why?
| | Standard of Care | 1 | 2025 | 81 | 0.050 |
Why?
| | Infant Mortality | 1 | 2005 | 128 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2024 | 83 | 0.050 |
Why?
| | Chest Pain | 1 | 2005 | 99 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2005 | 85 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 146 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2008 | 892 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 403 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2383 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 102 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 32 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 396 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 1036 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2013 | 1372 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5428 | 0.050 |
Why?
| | Syndrome | 2 | 2014 | 381 | 0.050 |
Why?
| | Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| | ortho-Aminobenzoates | 1 | 2022 | 10 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2025 | 297 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 340 | 0.050 |
Why?
| | Risk Factors | 5 | 2018 | 10919 | 0.050 |
Why?
| | E-Selectin | 1 | 2023 | 61 | 0.050 |
Why?
| | Oxygen | 1 | 2008 | 981 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 397 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 172 | 0.050 |
Why?
| | Medical Records | 1 | 2023 | 192 | 0.050 |
Why?
| | Glycolipids | 1 | 2023 | 53 | 0.050 |
Why?
| | Agriculture | 1 | 2022 | 94 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 750 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 643 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2025 | 560 | 0.040 |
Why?
| | P-Selectin | 1 | 2021 | 29 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2009 | 736 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 562 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1103 | 0.040 |
Why?
| | Colorado | 3 | 2024 | 4556 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2934 | 0.040 |
Why?
| | Blood Pressure | 3 | 2018 | 1782 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2021 | 8 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 7 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 6 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2021 | 17 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 20 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 50 | 0.040 |
Why?
| | Ovulation Induction | 1 | 2021 | 65 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 574 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 61 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1547 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 539 | 0.040 |
Why?
| | von Willebrand Factor | 2 | 1998 | 85 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2004 | 559 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 207 | 0.040 |
Why?
| | Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| | Metals | 1 | 2021 | 136 | 0.040 |
Why?
| | Cryopreservation | 1 | 2021 | 113 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 266 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 217 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 84 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3634 | 0.040 |
Why?
| | HIV Infections | 1 | 1994 | 3195 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2823 | 0.030 |
Why?
| | Rats | 2 | 2019 | 5585 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2019 | 335 | 0.030 |
Why?
| | Proteinuria | 1 | 2018 | 104 | 0.030 |
Why?
| | Endothelins | 1 | 2018 | 61 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2018 | 159 | 0.030 |
Why?
| | Thrombomodulin | 1 | 1998 | 15 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 1752 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 152 | 0.030 |
Why?
| | Body Height | 1 | 2018 | 203 | 0.030 |
Why?
| | Victoria | 1 | 2017 | 22 | 0.030 |
Why?
| | Public Health Practice | 1 | 2017 | 63 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 782 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 770 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2016 | 11 | 0.030 |
Why?
| | Fish Proteins | 1 | 2016 | 12 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 170 | 0.030 |
Why?
| | Bile | 1 | 2016 | 26 | 0.030 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 44 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1023 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 157 | 0.030 |
Why?
| | Pilot Projects | 2 | 2016 | 1898 | 0.030 |
Why?
| | Polychlorinated Biphenyls | 1 | 2016 | 11 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1062 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 338 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 208 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 71 | 0.030 |
Why?
| | Community Health Services | 1 | 2017 | 231 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5925 | 0.030 |
Why?
| | Odorants | 1 | 2016 | 114 | 0.030 |
Why?
| | Mononuclear Phagocyte System | 1 | 1995 | 10 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 1995 | 21 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2805 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 1995 | 14 | 0.030 |
Why?
| | Arginase | 1 | 2015 | 26 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3916 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 297 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 2016 | 119 | 0.030 |
Why?
| | Vitamin B 6 Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| | Amino Acids, Sulfur | 1 | 1994 | 8 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 196 | 0.030 |
Why?
| | Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| | beta 2-Glycoprotein I | 1 | 1994 | 5 | 0.030 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1994 | 6 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2014 | 55 | 0.030 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1994 | 7 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 132 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 108 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1996 | 274 | 0.030 |
Why?
| | Blood Platelets | 1 | 1998 | 379 | 0.030 |
Why?
| | Interview, Psychological | 1 | 2014 | 95 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 115 | 0.030 |
Why?
| | Folic Acid Deficiency | 1 | 1994 | 49 | 0.030 |
Why?
| | Automation | 1 | 2014 | 104 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 149 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 400 | 0.030 |
Why?
| | Penicillins | 1 | 2014 | 62 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 70 | 0.030 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1994 | 80 | 0.030 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 76 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 450 | 0.030 |
Why?
| | Hematologic Tests | 1 | 1994 | 22 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2094 | 0.030 |
Why?
| | Homocysteine | 1 | 1994 | 152 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 109 | 0.030 |
Why?
| | Smegmamorpha | 1 | 2013 | 6 | 0.020 |
Why?
| | DNA Damage | 1 | 2016 | 437 | 0.020 |
Why?
| | Ownership | 1 | 2014 | 115 | 0.020 |
Why?
| | Carrier Proteins | 2 | 1995 | 729 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2015 | 370 | 0.020 |
Why?
| | Catalase | 1 | 2013 | 134 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 88 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2014 | 149 | 0.020 |
Why?
| | Personnel Selection | 1 | 2014 | 91 | 0.020 |
Why?
| | Mood Disorders | 1 | 2014 | 144 | 0.020 |
Why?
| | Folic Acid | 1 | 1995 | 198 | 0.020 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 20 | 0.020 |
Why?
| | Professional Role | 1 | 2014 | 170 | 0.020 |
Why?
| | Liver Failure, Acute | 1 | 1994 | 68 | 0.020 |
Why?
| | Brain Diseases | 1 | 1994 | 155 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 134 | 0.020 |
Why?
| | Permeability | 1 | 2013 | 169 | 0.020 |
Why?
| | Methylamines | 1 | 2013 | 39 | 0.020 |
Why?
| | Cysteine | 1 | 1994 | 211 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2014 | 280 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 525 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 33 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 372 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 520 | 0.020 |
Why?
| | Minority Groups | 1 | 2014 | 285 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 780 | 0.020 |
Why?
| | Glycoproteins | 1 | 1994 | 354 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2015 | 252 | 0.020 |
Why?
| | Social Behavior | 1 | 2014 | 284 | 0.020 |
Why?
| | Choline | 1 | 2013 | 138 | 0.020 |
Why?
| | Perioperative Care | 1 | 2014 | 231 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 373 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 971 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 308 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 73 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 276 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 298 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 588 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2884 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3937 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2011 | 60 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 199 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 835 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 337 | 0.020 |
Why?
| | Public Health | 1 | 2016 | 574 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 196 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1330 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 848 | 0.020 |
Why?
| | Hemodynamics | 2 | 2011 | 1118 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1994 | 327 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2018 | 962 | 0.020 |
Why?
| | Purines | 1 | 2011 | 187 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 667 | 0.020 |
Why?
| | Communication | 1 | 2016 | 977 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3130 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 391 | 0.020 |
Why?
| | Walking | 1 | 2014 | 545 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2514 | 0.020 |
Why?
| | Pediatrics | 1 | 2017 | 1125 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2525 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 222 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 636 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1491 | 0.020 |
Why?
| | Sepsis | 1 | 1995 | 664 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 630 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1478 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1857 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1662 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2007 | 10 | 0.020 |
Why?
| | Infant | 3 | 2014 | 10091 | 0.020 |
Why?
| | Calcinosis | 1 | 2008 | 234 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 267 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 151 | 0.010 |
Why?
| | Health Personnel | 1 | 2013 | 757 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2191 | 0.010 |
Why?
| | Health Services | 1 | 2007 | 113 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2123 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1791 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2018 | 2977 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1764 | 0.010 |
Why?
| | Mental Disorders | 1 | 1994 | 1171 | 0.010 |
Why?
| | Program Development | 1 | 2007 | 368 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1995 | 125 | 0.010 |
Why?
| | Isotope Labeling | 2 | 1995 | 82 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 867 | 0.010 |
Why?
| | Critical Illness | 1 | 2010 | 900 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2007 | 554 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2139 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 396 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2007 | 869 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2008 | 1197 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2008 | 1244 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 2007 | 948 | 0.010 |
Why?
| | Physicians | 1 | 2008 | 956 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1996 | 105 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 207 | 0.010 |
Why?
| | Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| | 4-Aminobenzoic Acid | 1 | 1995 | 8 | 0.010 |
Why?
| | Vacuoles | 1 | 1995 | 38 | 0.010 |
Why?
| | Lactobacillus | 1 | 1995 | 28 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1995 | 116 | 0.010 |
Why?
| | Reference Standards | 1 | 1995 | 177 | 0.010 |
Why?
| | Carbon Isotopes | 1 | 1995 | 143 | 0.010 |
Why?
| | Aspartic Acid | 1 | 1994 | 88 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1994 | 84 | 0.010 |
Why?
| | Deuterium | 1 | 1994 | 102 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 344 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 798 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 229 | 0.010 |
Why?
| | Cattle | 1 | 1995 | 946 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 2000 | 0.000 |
Why?
| | Brain | 1 | 1994 | 2969 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|